PRFX
NASDAQ · Pharmaceuticals
Prf Technologies Ltd
$0.87
+0.11 (+14.77%)
Financial Highlights (FY 2026)
Revenue
75.9K
Net Income
-21,642,306
Gross Margin
-311.8%
Profit Margin
-28,458.8%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | -311.8% | 53.5% | 53.5% | 53.5% |
| Operating Margin | -30,129.4% | 31.4% | 29.8% | 28.9% |
| Profit Margin | -28,458.8% | 21.7% | 23.3% | 21.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 75.9K | 3.33M | 3.45M | 3.63M |
| Gross Profit | -236,763 | 1.78M | 1.85M | 1.94M |
| Operating Income | -22,881,479 | 1.04M | 1.03M | 1.05M |
| Net Income | -21,642,306 | 722.6K | 805.0K | 796.5K |
| Gross Margin | -311.8% | 53.5% | 53.5% | 53.5% |
| Operating Margin | -30,129.4% | 31.4% | 29.8% | 28.9% |
| Profit Margin | -28,458.8% | 21.7% | 23.3% | 21.9% |
| Rev Growth | — | -7.5% | +9.4% | +15.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 4.88M | 5.12M | 5.00M |
| Total Equity | — | 8.55M | 7.87M | 7.95M |
| D/E Ratio | — | 0.57 | 0.65 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -19,517,323 | 1.33M | 1.25M | 1.35M |
| Free Cash Flow | — | 449.2K | 396.5K | 453.1K |